

Supplemental material

Supplemental Table 1. Group differences by age of death, sex, and ApoE status

Supplemental Table 2. Clinical diagnoses by neurodegenerative disease group

Supplemental Table 3. CPC associations with co-pathology

Supplemental Table 1. Group differences by age of death, sex, and ApoE status

Group	Age at death			Sex		APOE $\epsilon 4$		APOE $\epsilon 2$	
	t-stat	df	p-value	x2	p-value	x2	p-value	x2	p-value
<i>iAD</i>	-5.08	104	<0.001	0.00	0.962	2.08	0.124	19.24	0.003
<i>hAD</i>	-3.6	113	<0.001	2.65	0.102	118.33	<0.001	383.98	<0.001
CBD	2.19	66	0.016	3.18	0.083	4.87	0.085	1.88	0.230
PiD	0.80	20	0.215	0.23	0.641	2.44	0.223	4.05	0.139
PSP	-3.46	120	<0.001	1.67	0.210	4.36	0.079	0.82	0.395
ALS	3.36	135	0.001	2.96	0.094	4.37	0.061	30.20	<0.001
FTD	0.37	125	0.356	0.04	0.850	3.02	0.125	6.07	0.040
<i>hFTD</i>	2.04	50	0.023	0.38	0.547	0.06	0.810	4.19	0.105
MSA	1.65	59	0.053	0.62	0.441	0.40	0.569	19.89	0.010
<i>bLBD</i>	-2.55	53	0.007	4.70	0.060	0.28	0.582	1.51	0.287
<i>lLBD</i>	-5.50	106	<0.001	24.16	<0.001	1.92	0.217	15.64	0.008
<i>nLBD</i>	-3.54	122	<0.001	17.00	<0.001	13.54	<0.001	169.22	<0.001

Supplemental Table 2. Clinical diagnoses by neurodegenerative disease group

Clinical/Group	MPG	<i>i</i> AD	<i>h</i> AD	PiD	CBD	PSP	ALS	FTLD -TDP	<i>h</i> TDP	MSA	<i>b</i> LBD	<i>l</i> LBD	<i>n</i> LBD
Alzheimer's disease													
<i>Possible</i>		2¹	10					2			1		4
<i>Probable</i>		15	107	0	1	1	1	6					5
Amyotrophic lateral sclerosis													
<i>Suspected</i>						1	3						
<i>Possible</i>							5						
<i>Probable</i>							10						
<i>Definite</i>							71		8				
<i>with MCI</i>							3		1				
<i>with FTD</i>							5	1	5				
Cerebrovascular disease²			2						1	2			
Cognitive impairment³	1	2	9								1		
Corticobasal syndrome	1	1	13	1	11	4		3	2				3
Dementia NOS			2			1		1					1
Dementia with Lewy bodies		3	11		1	2					1	3	18
Frontotemporal degeneration													
<i>bvFTD</i>	1		5	7	2	3		17	5				
NOS⁴	1	1	6	5	2			10	2				
<i>PPA (Logopenic)</i>		3	9		1			2		1			
<i>PPA (NOS)</i>			1			1		1					
<i>PPA (PNFA)</i>			4		4	1		3					
<i>PPA (SD)</i>			3	1				8					1
Motor neuron disease⁵		1					4						
Multiple system atrophy						1		1		17	1	1	1

No impairment⁶	64	5	2								2		
Parkinson's disease													
<i>PD</i>	1	5	1			1	1		4	5	13	7	
<i>PD/MCI</i>						1				4	2	1	
<i>PDD</i>		4	3			1			1	5	18	38	
Posterior cortical atrophy			3										1
Progressive supranuclear palsy					7	32			1	1			1
Schizophrenia			3										
Rare⁷	3	1	2				2						
Clinical unavailable		3	5	1		1	5						
Total	72	46	201	15	29	51	108	55	25	26	20	37	81
CPC specificity (n)	64	17	119	13	11	32	101	42	21	17	9	36	64
CPC specificity (%)	89%	37%	59%	87%	38%	63%	92%	76%	84%	65%	45%	97%	79%

¹ Cases highlighted in bold have a strong clinicopathological correlation.

² includes vascular dementia.

³ includes amnesic and non-amnesic mild cognitive impairment.

⁴ includes both FTLN-NOS and FTD-NOS.

⁵ includes primary lateral sclerosis and progressive muscular atrophy.

⁶ No cognitive or motor impairments.

⁷ includes bipolar disease, depression, dystonia, hydrocephalus and other rare diagnoses of n<3.

Supplemental Table 3. CPC associations with co-pathology

Group	OR¹	95% CI		p-value
MPG	2.47	0.47	12.90	0.28
<i>i</i> AD	0.68	0.19	2.45	0.55
<i>h</i> AD	1.00	0.53	1.90	0.99
PiD	0.39	0.01	14.82	0.61
CBD	0.28	0.04	1.94	0.20
PSP	0.20	0.04	1.06	0.06
ALS	0.64	0.03	12.80	0.77
FTD-TDP	0.68	0.16	2.91	0.60
<i>h</i> TDP	7.28	0.38	141.27	0.19
MSA	1.94	0.22	16.96	0.55
<i>b</i> LBD	0.37	0.03	5.10	0.45
<i>l</i> LBD	0.00	0.00	-	0.98
<i>n</i> LBD	0.00	0.00	2.8E202	0.96

¹ Predictor is CPC specificity and covariates are gender and age.